An unexplained death at a Russian plague research institute has prompted international scrutiny. The incident raises questions about laboratory safety, transparent reporting, and infection prevention preparedness while the cause remains unconfirmed.
|Articles|January 25, 2017
NIH Advances Understanding of Defenses Against Antibiotic-Resistant Klebsiella Bacteria
Advertisement
Klebsiella bacteria cause about 10 percent of all hospital-acquired infections in the United States. K. pneumoniae sequence type 258 (ST258) is one of the Carbapenem-Resistant Enterobacteriaceae organisms labeled an urgent threat by the Centers for Disease Control and Prevention. This strain of bacteria is particularly concerning because it is resistant to most antibiotics and kills nearly half of people with bloodstream infections.
National Institutes of Health (NIH) scientists and their colleagues seeking alternatives to antibiotics report that an antibody-based therapy approach may be useful against ST258 bacteria. Studies of modified human blood samples showed that a component of the innate immune system called the complement system is pivotal to killing ST258. The complement system includes nine proteins (C1-9) that help protect against bacterial infections, a process aided by antibodies.
Their study determined that killing of ST258 corresponds with a portion of the complement system known as the membrane attack complex (C5b-C9), which contacts bacterial surfaces. Blood depleted of antibodies and/or the complement system had a significantly reduced ability to kill antibiotic-resistant ST258 bacteria.
The scientists, ultimately hoping to develop new tools to treat and prevent these infections, now plan to test a modified antibody against ST258 in laboratory blood and animal infection models. They also plan to learn more about the complement system in people with K. pneumoniae bloodstream infections. They note that ST258 bacteria reside harmlessly in most healthy people; infection is usually of significant concern only for those in healthcare settings suffering from co-existing conditions or diseases.
Scientists at NIH's National Institute of Allergy and Infectious Diseases (NIAID) led the study with collaborators from New Jersey Medical School-Rutgers University.
Reference: DeLeo F, et al. Survival of carbapenem-resistant ST258 Klebsiella pneumoniae in human blood. Antimicrobial Agents and Chemotherapy DOI: 10.1128/AAC.02533-16 (2017).
Source: NIH/National Institute of Allergy and Infectious Diseases
Advertisement
Related to this article
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.
This week's coverage in Infection Control Today centered on a common thread: the systems, partnerships, and data that let infection prevention teams catch problems before patients are harmed.
UPMC’s genomic surveillance initiative earned national recognition for patient safety. Alexander Sundermann, DrPH, CIC, FAPIC, AL-CIP, explains how the award could help infection preventionists secure leadership support and sustainable funding for earlier outbreak detection.
Knowing the protocol is only the beginning. In The Clean Bite, Sherrie Busby explores how explaining the why, addressing staff concerns, and creating clear procedures can help dental teams make infection control part of everyday practice.
What might infection prevention rounds miss when visible conditions dominate the conversation? Tommy Davis, PhD, CMIP, a member of ICT's executive advisory board, makes the case for structured observations of clinical workflows, shared accountability, and greater attention to environmental services staff’s insights.
A proposed $27.7 million reduction in AHRQ funding raises questions about support for infection prevention research and implementation. Here is what the September 25 announcement identifies, as well as what remains unknown about specific IPC programs.
Advertisement
Advertisement